Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 13/20 | 0.44 |
| ▸ | F10 | P00742 | 13/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 13/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739985 | 0.91 | SLC6A3 (0.49) | F2F10PRSS1PDK2SLC6A4 | |
| SCHEMBL737445 | 0.90 | DHODH (0.38) | F2F10PRSS1PDK2LTB4R | |
| SCHEMBL2529138 | 0.88 | PDK2 (0.45) | F2F10PRSS1PDK2SLC6A4 | |
| SCHEMBL23778641 | 0.87 | KDM4E (0.39) | F2F10PRSS1PDK2SLC6A4 | |
| SCHEMBL362563 | 0.87 | KDM4E (0.39) | F2F10PRSS1PDK2SLC6A4 | |
| SCHEMBL3108151 | 0.87 | PDK2 (0.36) | F2F10PRSS1PDK2CA1 | |
| SCHEMBL738671 | 0.86 | PDK2 (0.36) | F2F10PRSS1PDK2SLC6A4 | |
| SCHEMBL11960920 | 0.86 | ABL1 (0.44) | F2F10PRSS1PDK2CA1 | |
| SCHEMBL738428 | 0.86 | NOTUM (0.39) | F2F10PRSS1PDK2CA1 | |
| SCHEMBL738679 | 0.86 | CA1 (0.37) | F2F10PRSS1PDK2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 627 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024127026-A1 | MEMBRANE FILTRATION-ASSISTED SOLUTION PHASE OLIGONUCLEOTIDE SYNTHESIS | Exactmer Limited (GB) | 2024-06-20 | — | — | WO | claimed |
| US-20240075150-A1 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | ASCENDIS PHARMA A/S (DK) | 2024-03-07 | — | — | US | claimed |
| EP-4313154-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD Therapeutics Limited (HK) | 2024-02-07 | — | — | EP | claimed |
| US-20230331934-A1 | NEW HYDROGELS | LEIBNIZ-INSTITUT FÜR NEUE MATERIALIEN GEMEINNÜTZIGE GMBH (DE) | 2023-10-19 | — | — | US | claimed |
| EP-4218795-A2 | PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS | Ascendis Pharma Bone Diseases A/S (DK) | 2023-08-02 | — | — | EP | claimed |
| EP-4192508-A1 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | Ascendis Pharma A/S (DK) | 2023-06-14 | — | — | EP | claimed |
| US-20230110994-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | ASCENDIS PHARMA A/S (DK) | 2023-04-13 | — | — | US | claimed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | claimed |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2022-12-22 | — | — | US | claimed |
| EP-4084872-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | Ascendis Pharma A/S (DK) | 2022-11-09 | — | — | EP | claimed |
| US-20100267886-A1 | USE OF HIGHLY BRANCHED POLYMERS IN POLYMER DISPERSIONS FOR GLOSS COLOURS | BASF SE (DE) | 2010-10-21 | — | — | US | claimed |
| US-20090093597-A1 | SYNTHESIS OF PARTICLES IN DENDRITIC STRUCTURES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2009-04-09 | — | — | US | claimed |
| JP-2008545621-A | — | — | 2008-12-18 | — | — | JP | claimed |
| EP-1877103-A2 | DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY | Dendritic Nanotechnologies, Inc. (US) | 2008-01-16 | — | — | EP | claimed |
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-12-27 | — | — | US | claimed |
| US-20070110810-A1 | Transdermal drug delivery systems, devices, and methods employing hydrogels | TRANSCUTANEOUS TECHNOLOGIES INC. (JP) | 2007-05-17 | — | — | US | claimed |
| WO-2007041119-A1 | TRANSDERMAL DRUG DELIVERY SYSTEMS, DEVICES, AND METHODS EMPLOYING HYDROGELS | TTI ELLEBEAU, INC. (JP) | 2007-04-12 | — | — | WO | claimed |
| WO-2006115547-A2 | DENDRITIC POLYMERS WITH ENHANCED AMPLIFICATION AND INTERIOR FUNCTIONALITY | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2006-11-02 | — | — | WO | claimed |
| US-6030738-A | HAVING CHARGE CONTROL PROPERTIES AND HIGH THERMAL STABILITY; COMPOUNDS ARE PREFERENTIALLY WITHOUT INHERENT COLOR AND HAVE GOOD DISPERSIBILITY IN CUSTOMARY TONER, POWDER COATING AND ELECTRET BINDERS | CLARIANT GMBH (DE) | 2000-02-29 | — | — | US | claimed |
| US-5738864-A | COVALENT COUPLING THROUGH LINKING SPACER GROUPS TO MACROMOLECULES THAT CAN SERVE AS RELATIVELY INERT POLYMERIC DRUG CARRIERS IN BIOLOGICAL SYSTEMS; SIDE EFFECT REDUCTION | EUROPEAN COMMUNITY (DE) | 1998-04-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | MYD88, TLR3, TMEM97 | F2 3712/4885F10 3424/4885PRSS1 2509/4885 |
| US-20240075150-A1 | CONJUGATES COMPRISING REVERSIBLE LINKERS AND USES THEREOF | CD44, PTMS, MSN | F2 3811/4885F10 3853/4885PRSS1 4240/4885 |
| US-20230110994-A1 | CONJUGATES UNDERGOING INTRAMOLECULAR REARRANGEMENTS | BCR, DHFR, ABL1 | F2 1595/4885F10 2458/4885PRSS1 3908/4885 |
| US-20220401561-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, SSB, DNPEP | F2 1812/4885F10 1337/4885PRSS1 1861/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | F2 1559/4885F10 3670/4885PRSS1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.